AmpliPhi Biosciences (NYSEAMERICAN:APHB) saw a large decrease in short interest in May. As of May 15th, there was short interest totalling 858,583 shares, a decrease of 7.7% from the April 30th total of 929,998 shares. Based on an average daily trading volume, of 108,394 shares, the days-to-cover ratio is presently 7.9 days. Currently, 5.5% of the shares of the company are sold short.
Separately, HC Wainwright set a $6.00 target price on shares of AmpliPhi Biosciences and gave the stock a “buy” rating in a research note on Wednesday, May 16th.
AmpliPhi Biosciences opened at $1.21 on Friday, according to MarketBeat.com. AmpliPhi Biosciences has a 1 year low of $0.67 and a 1 year high of $2.05.
AmpliPhi Biosciences (NYSEAMERICAN:APHB) last posted its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.11. AmpliPhi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million.
In other AmpliPhi Biosciences news, Director Jeremy Curnock Cook purchased 354,315 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The shares were bought at an average cost of $1.54 per share, for a total transaction of $545,645.10. Following the purchase, the director now owns 330 shares of the company’s stock, valued at approximately $508.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
A hedge fund recently bought a new stake in AmpliPhi Biosciences stock. Sabby Management LLC bought a new position in AmpliPhi Biosciences (NYSEAMERICAN:APHB) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 831,961 shares of the biotechnology company’s stock, valued at approximately $907,000. Sabby Management LLC owned approximately 5.05% of AmpliPhi Biosciences at the end of the most recent reporting period.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
Receive News & Ratings for AmpliPhi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmpliPhi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.